Opinion: Cancer vaccines are finally here. How do we get them to patients?

The personalized cancer vaccine field is moving from proof of concept toward systematic pipeline building. On the regulatory side, Merck's subcutaneous KEYTRUDA QLEX (pembrolizumab plus berahyaluronidase alfa) has been approved by FDA, with indications covering unresectable or metastatic melanoma and adjuvant treatment of Stage IIB, IIC, or III melanoma following complete resection ^[1][2]. On the registry side, sponsor Merck Sharp & Dohme has multiple Phase 3 trials of intismeran autogene (V940) plus pembrolizumab recruiting, including a randomized double-blind NSCLC study with disease-free survival (DFS) as primary endpoint, planned enrollment of 680, started October 2024 with primary completion expected May 2033 ^[3]; another three-arm study in high-risk NSCLC with placebo control and planned enrollment of 876 is planned to start May 2026 ^[4]. Industry analysis has suggested the melanoma Phase 3 success has positive readthrough to other solid tumour indications , and NCI is backing a $200 million cancer vaccines research initiative ^[5].

The core fact of this opinion piece: at the ESMO annual congress, a Phase 3 study showed the "cancer vaccine" intismeran autogene plus pembrolizumab reduced the risk of recurrence or death by 42% versus pembrolizumab alone; the authors call it the first neoantigen mRNA therapy to meet a Phase 3 endpoint in oncology. The piece shifts the question from whether vaccines work to how to accelerate development and broaden access, identifying four bottlenecks: a regulatory framework not built for n-of-1 therapeutics, a fragmented delivery chain with no one accountable end-to-end, misaligned payer incentives (health plans with one-to-two-year member churn lack incentive to pay for expensive prevention), and slow clinical guidelines. The authors note NCI and the Foundation for NIH will launch a $200 million public-private partnership, the Therapeutic Cancer Vaccines Initiative, aiming to build trial networks, data standards, and infrastructure to bring vaccines to patients within the decade (needs verification).

Relative to existing material, the piece advances the discussion by framing intismeran's 42% benefit within a systemic view of payment, guidelines, regulation, and supply chain, rather than the efficacy number alone. This echoes the registry-level Phase 3 expansion across tumor types — two NSCLC adjuvant Phase 3 trials with planned enrollments of 680 and 876 ^[3][4] — while the article argues that translating such pipelines into access requires pre-designed regulatory pathways (validate the neoantigen-selection and manufacturing platform, then extend to new cancers with rigorous post-market evidence), payment models (multiyear or outcomes-based contracts), and guideline mechanisms (how real-world data can rapidly update platform-therapy recommendations). A reconciliation note: media reports also cite a 49% reduction in melanoma recurrence risk (RFS HR 0.510), inconsistent with the article's 42%, and that number appears only in industry media (media-exclusive); readers should note the population, endpoint, or follow-up may differ ^[6] (needs verification)。

Information not yet disclosed or pending confirmation includes: the specific trial number of this Phase 3, full population definition and follow-up duration, overall survival data, regulatory filing timeline, and pricing; details of the Therapeutic Cancer Vaccines Initiative's funding structure and participants are also undisclosed. Key nodes to watch include enrollment and interim analyses of the two NSCLC Phase 3 trials in registries ^[4][3], and the implementation of NCI's $200 million initiative ^[5] (needs verification).